HC Wainwright reaffirmed their buy rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report sent to investors on Thursday. HC Wainwright currently has a $5.00 target price on the biotechnology company’s stock.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”,” HC Wainwright’s analyst wrote.
Separately, Zacks Investment Research lowered shares of Genocea Biosciences from a buy rating to a hold rating in a research report on Tuesday, October 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $4.20.
NASDAQ GNCA traded down $0.01 during mid-day trading on Thursday, reaching $0.65. 199,600 shares of the stock were exchanged, compared to its average volume of 736,136. Genocea Biosciences has a 1-year low of $0.49 and a 1-year high of $1.39. The firm has a market cap of $54.57 million, a P/E ratio of -0.33 and a beta of 1.00. The company has a debt-to-equity ratio of 0.95, a quick ratio of 6.84 and a current ratio of 6.84.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. As a group, equities analysts predict that Genocea Biosciences will post -0.47 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in GNCA. California State Teachers Retirement System boosted its position in Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 78,469 shares during the last quarter. LMR Partners LLP acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $175,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Genocea Biosciences in the 1st quarter valued at $177,000. DRW Securities LLC acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $205,000. Finally, Paloma Partners Management Co acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $343,000. Hedge funds and other institutional investors own 60.23% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.